ZAG-S&W represents Therapix Biosciences in $13.8 Million Initial Public Offering


Therapix is a specialty clinical-stage pharmaceutical company focused on technologies and assets based on cannabinoid pharmaceuticals.



Therapix is engaged in two drug development programs based on repurposing an FDA, .approved synthetic cannabinoid 
The ZAG-S&W team consisted of attorneys from Boston, New York and Tel Aviv, including Howard Berkenblit, Oded Har-Even and David Huberman, as well as Shy Baranov, Rob Condon, Ron Ben-Bassat, Boaz Shiffman and Hila Nahum represented them in this initial offering.

Read more